Source: Treatment.com
  • Treatment.com International Inc. (TRUE) symptom assessment tool is available on Google Play Store after a successful launch
  • Treatment Digital Health App is a doctor-built app and is driven by an intelligent digital health assistant
  • The app will provide access to advanced medical knowledge for widespread use
  • Doctors currently use Treatment’s AI software for their clinical assessments globally
  • Treatment.com International Inc. (TRUE) is down 3.23 per cent and is trading at $0.60 per share as of 12:07 p.m. EST

Treatment.com International Inc. (TRUE) symptom assessment tool, Treatment Digital Health App, is available on Google Play Store after a successful launch on the Apple App Store.

Treatment Digital Health App is a doctor-built app and is driven by an intelligent digital health assistant to allow people to take control of their health.

The app is powered by Treatment’s proprietary medical AI engine and its Global Library of Medicine (GLM). The app will provide access to advanced medical knowledge for widespread use.

The app’s health assessments aim to surpass the user’s expectations using up-to-date estimates of disease rates, current estimates of geographic variation, and the latest medical research.

Doctors currently use Treatment’s AI software to provide information for their clinical assessments globally. The same technology is used by leading medical schools to test students’ clinical skills.

John Fraser, CEO of Treatment.com, stated,

“We’ve been pleased to receive overwhelmingly positive reviews on the Apple App Store for our first-even product launch, including from qualified sources like medical doctors… we are confident that this launch on the Google Play Store will go a huge step further towards fulfilling the growing, global need for up-to-date, credible health information,”
Treatment.com is a Vancouver-based healthcare technology company that is harnessing the power of AI to help global citizens improve their health through personalized recommendations and insights. 

Treatment.com International Inc. (TRUE) is down 3.23 per cent and is trading at $0.60 per share as of 12:07 p.m. EST.

More From The Market Online

This AI tech stock is growing exponentially: What you need to know

AI tech stock Metaguest.AI (CSE:METG) grows subscription sales and experience bookings by almost 10x since Q1 2023.
labratory work

PharmaTher locks in FDA-assigned goal date of abbreviated NDA

PharmaTher Holdings (CSE:PHRM) locks in its U.S. FDA-assigned goal date of abbreviated new drug application for Oct. 29, 2024.

4 stocks to consider after Microsoft’s 2024 study on AI at work

Microsoft (NASDAQ:MSFT) on Wednesday released the 2024 Work Trend Index, which looks into the state of artificial intelligence at work.